STOK vs. GHRS, OLMA, CALT, ZYME, PHAT, PHAR, LYEL, ORIC, IGMS, and SLN
Should you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include GH Research (GHRS), Olema Pharmaceuticals (OLMA), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Phathom Pharmaceuticals (PHAT), Pharming Group (PHAR), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), IGM Biosciences (IGMS), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
GH Research (NASDAQ:GHRS) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
Stoke Therapeutics received 81 more outperform votes than GH Research when rated by MarketBeat users. Likewise, 72.99% of users gave Stoke Therapeutics an outperform vote while only 67.86% of users gave GH Research an outperform vote.
GH Research has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
GH Research presently has a consensus target price of $36.67, indicating a potential upside of 180.76%. Stoke Therapeutics has a consensus target price of $20.57, indicating a potential upside of 74.33%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe GH Research is more favorable than Stoke Therapeutics.
In the previous week, Stoke Therapeutics had 16 more articles in the media than GH Research. MarketBeat recorded 29 mentions for Stoke Therapeutics and 13 mentions for GH Research. Stoke Therapeutics' average media sentiment score of 0.60 beat GH Research's score of 0.20 indicating that GH Research is being referred to more favorably in the media.
GH Research has higher earnings, but lower revenue than Stoke Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
56.9% of GH Research shares are owned by institutional investors. 11.3% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Stoke Therapeutics' return on equity of -14.56% beat GH Research's return on equity.
Summary
GH Research and Stoke Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Stoke Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Stoke Therapeutics Competitors List
Related Companies and Tools
